View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Factors that predict response to PEG-IFN 57<br />
14. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis<br />
B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European<br />
Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-42.<br />
15. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Longterm<br />
remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med<br />
1991;114:629-34.<br />
16. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis<br />
B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis<br />
(EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389-97.<br />
17. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients<br />
treated with interferon alfa. Gastroenterology 1993;105:1833-8.<br />
18. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Longterm<br />
follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis<br />
B. N Engl J Med 1996;334:1422-7.<br />
19. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C,<br />
So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated<br />
interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose<br />
reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-71.<br />
20. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song<br />
BC, Janssen HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following<br />
antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum<br />
hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.<br />
21. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson<br />
S, Condreay LD, Chien RN. Extended lamivudine treatment in patients with chronic hepatitis<br />
B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.<br />
Hepatology 2001;33:1527-32.<br />
22. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung<br />
NW. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J<br />
Gastroenterol Hepatol 2004;19:1276-82.<br />
23. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M,<br />
Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is<br />
rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65.<br />
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P,<br />
Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Longterm<br />
Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5<br />
Years. Gastroenterology 2006;131:1743-51.<br />
25. Cooksley G, Lau GKK, Liaw YF, Marcellin P, Chow WC, Thongsawat S, Gane E, Fried MW,<br />
Zahm FE. Effects of genotype and other baseline factors on response to peginterferon<br />
alfa-2a (40 kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large,<br />
randomised study. J Hepatol 2005;42:S30.